Search - tctmd.com

Displaying 61 - 80 of 127

Sort: Relevancy | Date

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

September 14, 2014

News Conference News TCT 2014

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

News Conference News TCT 2013

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

October 30, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Presenter: David Antoniucci

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Presenter: Young-Hak Kim

October 28, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

Advertisement

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Keynote Address Focuses on Newer DES, Problematic Subgroups

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

COMPARE II: BES, EES Show Similar Outcomes at Three Years

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

ABSORB III and IV Trials Aim to Prove Superiority of BVS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content